Students' Scientific Research Group of Systematic Reviews, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Kraków, Poland.
Ann Agric Environ Med. 2023 Jun 26;30(2):217-223. doi: 10.26444/aaem/162732. Epub 2023 May 16.
A number of studies indicate the presence of a thyroid-gut axis and the important influence of the gut microbiota on thyroid function. As prebiotics, probiotics and synbiotics show therapeutic potential in the treatment of intestinal dysbiosis, the aim of this review is to evaluate the efficacy of their supplementation in primary thyroid diseases.
Electronic databases (Ovid MEDLINE, Embase, CENTRAL), registers of clinical trials, and grey literature up to 6 October 2022 were searched for randomised controlled trials (RCTs) meeting pre-specified inclusion criteria. The protocol was registered in PROSPERO (CRD42021235054).
After screening 1,721 references, two RCTs were identified, which included 136 hypothyroid participants in total. Meta-analysis of the results after eight weeks of supplementation with predominantly Lactobacillus and Bifidobacterium strains indicated a clinically and statistically nonsignificant decrease in TSH (MD -0.19 mIU/L; 95% CI -0.43 to 0.06; I= 0%), and no effect on fT levels (MD 0.01 pg/mL; 95% CI-0.16 to 0.18; I= 0%). Data from single studies indicated no significant change in the levels of fT4, thyroid auto-antibodies, BMI, levothyroxine doses, and severity of symptoms measured with validated scales. Only constipation scores showed significant improvement (MD -8.71 points in the Faecal Incontinence Questionnaire; 95% CI -15.85 to -1.57; I= 0%).
Low-certainty evidence from two randomised trials, suggests that routine administration of probiotics, prebiotics or synbiotics may result in little to no benefit in patients with primary hypothyroidism.
多项研究表明存在甲状腺-肠道轴,肠道微生物群对甲状腺功能有重要影响。由于益生菌、益生元和合生菌在治疗肠道菌群失调方面显示出治疗潜力,因此本综述旨在评估其在原发性甲状腺疾病中的补充疗效。
对截至 2022 年 10 月 6 日的电子数据库(Ovid MEDLINE、Embase、CENTRAL)、临床试验注册处和灰色文献进行了检索,以寻找符合预定义纳入标准的随机对照试验(RCT)。该方案已在 PROSPERO(CRD42021235054)中注册。
筛选出 1721 篇参考文献后,确定了两项 RCT,总共纳入了 136 名甲状腺功能减退症患者。对补充主要为乳杆菌和双歧杆菌菌株 8 周后的结果进行荟萃分析表明,TSH 水平的临床和统计学意义无显著降低(MD-0.19 mIU/L;95% CI-0.43 至 0.06;I=0%),游离 T 水平也无影响(MD 0.01 pg/mL;95% CI-0.16 至 0.18;I=0%)。单项研究的数据表明,游离 T4、甲状腺自身抗体、BMI、左甲状腺素剂量和用经过验证的量表测量的症状严重程度无显著变化。只有便秘评分显示出显著改善(粪便失禁问卷的 MD-8.71 分;95% CI-15.85 至-1.57;I=0%)。
两项随机试验的低确定性证据表明,原发性甲状腺功能减退症患者常规给予益生菌、益生元或合生菌可能几乎没有益处。